Combination therapy with acetyl-leucine and miglustat
WO2020178721A1
Leucine, acetyl leucine, and related analogs for treating disease
WO2020115715A1
Deuterated analogs of acetyl-leucine
WO2019159110A1
Therapeutic agents for treating restless legs syndrome
US2020338034A1
Therapeutic agents for improved mobility and cognitive function and for treating neurodegenerative diseases and lysosomal storage disorders
US2021085659A1
Betahistine, or a pharmaceutically acceptable salt thereof, and a monoamine oxidase inhibitor, for use in the treatment or prevention of one or more symptoms of vertigo in a subject
KR20200074170A
Treatment for neurodegenerative diseases
EP3482754A1
Pharmaceutical compositions and uses directed to lysosomal storage disorders
ME03454B
Therapeutic agents for neurodegenerative diseases
GB201711677D0
Combination treatment
GB201709459D0
Treatment for migraine
GB201706854D0
Therapeutic agents for lysosomal storage disorders
GB201706867D0
Therapeutic agents for neurodegenerative diseases, lysosomal storage disorders and neurodegenerative diseases associated with defects in lysosomal storage
CN109069463A
For improving the Acetylleucine or its pharmaceutically acceptable salt of locomitivity and cognitive function
GB201705762D0
Therapeutic agents for lysosomal storage disorders
GB201705766D0
Therapeutic agents for neurodegenerative diseases, lysosomal storage disorders and neurodegenerative diseases associated with defects in lysosomal storage
GB201704949D0
Combination treatment
GB201702551D0
Therapeutic agents for neurodegenerative diseases, lysosomal storage disorders and neurodegenerative diseases associated with defects in lysosomal storage
GB201702552D0
Therapeutic agents for lysosomal storage disorders
GB201613829D0
Therapeutic agents for neurodegenerative diseases, lysosomal storage disorders and neurodegenerative diseases associated with defects in lysosomal storage
